AkamisBio
@AkamisBio
Followers
1K
Following
161
Media
103
Statuses
316
Akamis Bio uses its T-SIGn® platform to enter solid tumors & turn them into “drug factories” to enable the immune system’s attack on the tumor from the inside.
Cambridge, MA
Joined December 2010
We’re pleased to stand with @FightCRC in their commitment to provide patients, families, and caregivers with clear, accessible information about colorectal cancer research and clinical study options. Fight CRC's latest newsletter highlights why bringing science to everyone and
0
0
1
We share the Colorectal Cancer Alliance’s belief that understanding all treatment options, including clinical trials, empowers patients facing colorectal cancer to make the most informed decisions possible. At Akamis Bio, we’re advancing that mission through the Ph1b FORTRESS
fortressstudy.org
Discover eligibility, locations, and benefits of the FORTRESS Study pairing NG-350A with standard rectal cancer treatment.
Understanding all treatment options, including clinical trials, empowers patients to make informed choices, opening the door to hope, innovation, and more time with the people they love. Kate’s mom, Lynn Shin, was diagnosed with Stage IV terminal rectal cancer, but clinical
0
0
1
Congratulations to our partner Xuanzhu Biopharma on a successful Hong Kong stock exchange IPO, highlighting the strength of its programs, pipeline and team. We’re proud of our collaboration on NG-350A, Akamis' lead oncolytic immunotherapy, currently being studied in our Phase 1b
0
0
1
Akamis Bio today announced FDA Fast Track designation for NG-350A in mismatch-repair–proficient (pMMR) locally advanced rectal cancer (LARC). This is an important recognition of the significant unmet need in pMMR LARC as we advance NG-350A through our Ph1b FORTRESS study
0
0
1
We’re pleased to welcome C4 Therapeutics CEO Andrew Hirsch to our Board of Directors. His extensive industry leadership, as well as his strategic and operational expertise in advancing novel therapies will be invaluable as we unlock the full potential of our immunotherapeutic
0
0
1
We are thrilled to announce the appointment of three experienced biopharma executives to the Akamis Bio team to lead our Finance, CMC and Business Development/Alliance Management functions. Read today’s announcement here: https://t.co/e5wu3Xrq1s
0
0
1
We are pleased to announce enrollment of the first patient in our Phase 1b FORTRESS trial of NG-350A for the treatment of locally advanced rectal cancer (LARC), a key milestone toward advancing a novel immunotherapy and potentially transforming standard of care. Learn more:
0
0
0
Thrilled to announce the completion of Akamis Bio’s Series A Prime financing and new strategic partnership which provide funding to support the advancement of our lead oncology candidate, NG-350A, into a clinical proof-of-concept study in patients with locally advanced rectal
1
3
5
Tune in to the Careers in Discovery #podcast with @Tom_Froggatt to hear Samantha Bailey-Bucktrout discuss her #career and current role leading research at Akamis Bio, and the potential of systemically delivered T-SIGn therapeutics to treat solid tumors: https://t.co/5CXNHCSmC0
0
0
3
Samantha Bailey-Bucktrout will be speaking at the #PEGSEurope Conference to discuss how we use our T-SIGn platform to express novel antibody combinations, recent advances in our lead program NG-350A, and new transgene combinations to boost CAR-T activity: https://t.co/ZWn9jabTFR
0
1
3
Akamis Bio CEO Howard Davis, Ph.D., was featured on The Bio Report podcast with @dslevine where they discussed the potential of T-SIGn therapeutics to treat solid tumors both as monotherapies and in combination with a range of cell therapies. Listen now: https://t.co/uwSkJkbmrP
0
0
3
Akamis Bio will share data at #ASTRO2023 from the Phase 1 CEDAR study which showed improved responses in patients with locally advanced rectal #cancer treated with radiotherapy in combination with our adenovirus vector #technology, over radiation alone https://t.co/e3mqgB0Cwd
0
0
2
Learn more about Akamis Bio’s lead program, NG-350A, a Phase 1 immuno-stimulatory #genetherapy that aims to safely drive intra-tumoral expression of a potent CD-40 agonist to treat solid #cancer tumors:
akamisbio.com
With more than 200 patients treated across our clinical studies, T-SIGn® therapeutics have demonstrated a consistent safety & tolerability profile, as well as promising preliminary evidence of...
0
0
3
Akamis Bio is working to enhance #immunotherapy by addressing the safety and efficacy challenges of treating #solidtumors. Learn how our T-SIGn® therapeutics aim to drive a powerful tumor-specific immune response while avoiding systemic toxicity: https://t.co/qOVbYK7eVh
0
0
3
Check out this recent article from @_CellandGene featuring our CEO, Howard Davis, Ph.D., who discusses Akamis Bio’s portfolio of T-SIGn #therapeutics, our NG-350A clinical trial, and how T-SIGn is broadening the impact of cell therapy in #solidtumors: https://t.co/iXyikTmVzd
0
0
2
See how our T-SIGn® platform is working to advance cell therapies for solid tumors, with novel vectors that can help express target antigens to enhance the activation, survival, and efficacy of cell therapies in the #solidtumor setting https://t.co/K1lNSnJnuY
0
0
0
Akamis Bio’s T-SIGn therapeutics are designed to modulate the #tumor microenvironment, enabling the local production of potent immuno-therapeutics that drive robust anti-tumor immune responses to recognize, attack and clear solid tumors. Learn more: https://t.co/NwCVMDnkBe
0
0
1
Akamis Bio aims to transform the treatment of advanced #solidtumors, with I.V. administered, tumor-specific therapeutics that can generate a potent immune response and avoid systemic toxicity. Learn more about our T-SIGn® therapeutics platform: https://t.co/nULEnLzHYS
0
0
0
We are pleased to announce new leadership appointments at Akamis Bio! Learn more about our work to transform the delivery and efficacy of immuno-oncology treatments for solid tumors: https://t.co/uDF8ryTdnK
1
2
2